Insulet Co. (NASDAQ:PODD) Shares Sold by Rosenblum Silverman Sutton S F Inc. CA

Rosenblum Silverman Sutton S F Inc. CA cut its holdings in shares of Insulet Co. (NASDAQ:PODD) by 1.6% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 34,419 shares of the medical instruments supplier’s stock after selling 550 shares during the quarter. Insulet accounts for 2.3% of Rosenblum Silverman Sutton S F Inc. CA’s investment portfolio, making the stock its 15th largest position. Rosenblum Silverman Sutton S F Inc. CA’s holdings in Insulet were worth $8,986,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. SBI Securities Co. Ltd. purchased a new stake in shares of Insulet during the 4th quarter worth approximately $36,000. SRS Capital Advisors Inc. raised its position in Insulet by 43.1% in the fourth quarter. SRS Capital Advisors Inc. now owns 186 shares of the medical instruments supplier’s stock worth $49,000 after acquiring an additional 56 shares in the last quarter. TD Private Client Wealth LLC increased its holdings in shares of Insulet by 32.6% in the 3rd quarter. TD Private Client Wealth LLC now owns 228 shares of the medical instruments supplier’s stock valued at $53,000 after purchasing an additional 56 shares in the last quarter. Friedenthal Financial purchased a new stake in shares of Insulet during the 4th quarter worth approximately $57,000. Finally, Assetmark Inc. increased its position in shares of Insulet by 1,447.1% in the fourth quarter. Assetmark Inc. now owns 263 shares of the medical instruments supplier’s stock valued at $69,000 after buying an additional 246 shares in the last quarter.

Wall Street Analysts Forecast Growth

PODD has been the subject of several recent research reports. Stifel Nicolaus raised their price target on Insulet from $245.00 to $293.00 and gave the stock a “hold” rating in a research report on Friday, February 21st. JPMorgan Chase & Co. upped their price objective on Insulet from $280.00 to $330.00 and gave the stock an “overweight” rating in a report on Thursday, December 12th. Canaccord Genuity Group boosted their price objective on shares of Insulet from $304.00 to $324.00 and gave the stock a “buy” rating in a research note on Friday, February 21st. Piper Sandler increased their price objective on shares of Insulet from $285.00 to $310.00 and gave the company an “overweight” rating in a research report on Friday, February 21st. Finally, Citigroup boosted their price target on Insulet from $310.00 to $355.00 and gave the stock a “buy” rating in a research note on Friday, February 21st. Four equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $292.06.

Insider Transactions at Insulet

In related news, Director Wayne A.I. Frederick sold 1,825 shares of the stock in a transaction that occurred on Tuesday, March 25th. The shares were sold at an average price of $275.00, for a total transaction of $501,875.00. Following the sale, the director now owns 3,231 shares in the company, valued at approximately $888,525. This trade represents a 36.10 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Eric Benjamin sold 12,394 shares of the stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the completion of the transaction, the executive vice president now directly owns 11,383 shares of the company’s stock, valued at $3,187,240. This trade represents a 52.13 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.47% of the company’s stock.

Insulet Price Performance

Shares of PODD stock opened at $256.80 on Friday. Insulet Co. has a 52-week low of $160.19 and a 52-week high of $289.46. The firm’s 50 day moving average price is $270.56 and its two-hundred day moving average price is $259.45. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68. The stock has a market cap of $18.03 billion, a PE ratio of 44.35, a PEG ratio of 3.62 and a beta of 1.29.

Insulet (NASDAQ:PODD) last posted its earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.00 by $0.15. Insulet had a return on equity of 24.46% and a net margin of 20.19%. The business had revenue of $597.50 million during the quarter, compared to analysts’ expectations of $582.02 million. As a group, analysts forecast that Insulet Co. will post 3.92 EPS for the current year.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.